Jasper Therapeutics Inc JSPR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:30 AM EDT
26.26quote price arrow down-0.04 (-0.15%)
Volume
644
52 week range
4.00 - 31.01
Loading...
  • Open26.26
  • Day High26.26
  • Day Low26.26
  • Prev Close26.30
  • 52 Week High31.01
  • 52 Week High Date04/01/24
  • 52 Week Low4.00
  • 52 Week Low Date12/13/23

Key Stats

  • Market Cap395.578M
  • Shares Out15.06M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta2.23
  • YTD % Change233.33

KEY STATS

  • Open26.26
  • Day High26.26
  • Day Low26.26
  • Prev Close26.30
  • 52 Week High31.01
  • 52 Week High Date04/01/24
  • 52 Week Low4.00
  • 52 Week Low Date12/13/23
  • Market Cap395.578M
  • Shares Out15.06M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta2.23
  • YTD % Change233.33

RATIOS/PROFITABILITY

  • EPS (TTM)-19.69
  • P/E (TTM)-1.33
  • Fwd P/E (NTM)-5.62
  • EBITDA (TTM)-67.661M
  • ROE (TTM)-112.67%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/10/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Jasper Therapeutics Inc

 

Profile

MORE
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The...
Thomas Wiggans
Chairman of the Board
Ronald Martell
President, Chief Executive Officer, Director
Jeetinder Mahal
Chief Operating Officer
Herb Cross
Chief Financial Officer, Corporate Secretary
Address
2200 Bridge Pkwy Suite #102
Redwood City, CA
94065
United States

Top Peers

SYMBOLLASTCHG%CHG
PASG
Passage Bio Inc
1.25+0.02+1.63%
CRVS
Corvus Pharmaceuticals Inc
1.51+0.04+2.72%
PROK
ProKidney Corp
2.06-0.02-1.20%
ANTX
AN2 Therapeutics Inc
2.48-0.02-0.80%
ALVR
Allovir Inc
0.735-0.0111-1.4877%